List PLR Content Marketing Belize: 2016

Thursday, October 27, 2016

Lacrisert

Lacrisert is a brand name of ocular lubricant ophthalmic, approved by the FDA in the following formulation(s):

LACRISERT (hydroxypropyl cellulose - insert; ophthalmic)

Manufacturer: ATON

Approved Prior to Jan 1, 1982

Strength(s): 5MG ^[RLD]

Has a generic version of Lacrisert been approved?

No. There is currently no therapeutically equivalent version of Lacrisert available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lacrisert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Lacrisert.

Has a generic version of Spiriva been approved?

No. There is currently no therapeutically equivalent version of Spiriva available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Spiriva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Powders for inhalation
Patent 5,478,578
Issued: December 26, 1995
Inventor(s): Arnold; Klaus & Grass; Peter & Knecht; Adolf & Roos; Robert & Sluke; Gerhard & Thieme; Herbet & Wenzel; Joachim
Assignee(s): Boehringer Ingelheim KG
In order to control and optimize the amount of inhalable active substance released when drugs are administered as inhalation powders, the invention calls for the use of auxiliaries consisting of mixtures of coarser particles (average particle size>20 .mu.m) and finer particles (average particle size
Patent expiration dates:

December 26, 2012
✓
Drug product

Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Patent 6,777,423
Issued: August 17, 2004
Inventor(s): Rolf; Banholzer & Peter; Sieger & Christian; Kulinna & Michael; Trunk & Manfred; Graulich & Peter; Specht & Helmut; Meissner & Andreas; Mathes
Assignee(s): Boehringer Ingelheim Pharma KG
Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
Patent expiration dates:
- September 24, 2021
  ✓
  Drug substance
  ✓
  Drug product

Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Patent 6,908,928
Issued: June 21, 2005
Inventor(s): Banholzer; Rolf & Sieger; Peter & Kulinna; Christian & Trunk; Michael & Graulich; Manfred & Specht; Peter & Meissner; Helmut & Mathes; Andreas
Assignee(s): BI Pharma KG.
Crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
Patent expiration dates:
- September 24, 2021
  ✓
  Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  ✓
  Drug substance
  ✓
  Drug product
- September 24, 2021
  ✓
  Patent use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  ✓
  Drug substance
  ✓
  Drug product

Inhalable powder containing tiotropium
Patent 7,070,800
Issued: July 4, 2006
Inventor(s): Bechtold-Peters; Karoline & Walz; Michael & Boeck; Georg & Doerr; Rolf
Assignee(s): Boehringer Ingelheim Pharma KG
The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
Patent expiration dates:
- January 22, 2022
  ✓
  Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  ✓
  Drug product

Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Patent 7,309,707
Issued: December 18, 2007
Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
The invention relates to a crystalline micronisate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
Patent expiration dates:
- September 24, 2021
  ✓
  Drug substance
  ✓
  Drug product

Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Patent 7,642,268
Issued: January 5, 2010
Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
The invention relates to a crystalline micronisate of (1 α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
Patent expiration dates:
- September 24, 2021
  ✓
  Drug substance
  ✓
  Drug product

Dry powder inhaler
Patent 7,694,676
Issued: April 13, 2010
Inventor(s): Wachtel; Herbert
Assignee(s): Boehringer Ingelheim GmbH
An inhaler for inhaling powdered pharmaceutical compositions from capsules includes: a lower part; a plate which can be latched to the lower part and with which the lower part can be closed off; a capsule holder for receiving the capsules, this holder being adapted to be lowered into the lower part; a mouthpiece latchable to the plate; a lid which covers the mouthpiece in a closed position and latches it by means of a closure element, the lower part, the plate, the mouthpiece and the lid being hinged together by means of a single joint; and an actuating member which can be moved out a resting position and thereby interacts with at least one pin which can be made to pierce the capsule holder.
Patent expiration dates:
- March 12, 2027
  ✓
  Drug product

Method for the administration of an anticholinergic by inhalation
Patent 8,022,082
Issued: September 20, 2011
Inventor(s): Zierenberg; Bernd
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 μm, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 μm to 500 μm, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L containing the inhalable powder.
Patent expiration dates:
- January 19, 2026
  ✓
  Patent use: ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
  ✓
  Drug product

Process for preparing powder formulations
Patent RE38912
Issued: December 6, 2005
Inventor(s): Walz; Michael & Boeck; Georg
Assignee(s): Boehringer Ingelheim Pharma KG
The invention relates to a new process for producing powdered preparations for inhalation.
Patent expiration dates:
- October 11, 2021
  ✓
  Drug product

Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Patent RE39820
Issued: September 4, 2007
Inventor(s): Banholzer; Rolf & Bauer; Rudolf & Reichl; Richard
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
Compounds of the formula of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3α-(6β, 7β-epoxy)-tropanyl methobromide and R1 is 2-thienyl; (b) A is 3α-(6, 7dehydro)-tropanyl methobromide and R1 is 2-thienyl; (c) A is 3β-tropanyl methobromide and R1 is 2-thienyl; and, (d) A is 3α-(N-isopropyl)-nortropanyl methobromide and R1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
Patent expiration dates:
- January 30, 2018
  ✓
  Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- December 17, 2012 - PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM

Has a generic version of Singulair been approved?

No. There is currently no therapeutically equivalent version of Singulair available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Singulair. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
Patent 5,565,473
Issued: October 15, 1996
Inventor(s): Belley; Michel L. & Leger; Serge & Labelle; Marc & Roy; Patrick & Xiang; Yi B. & Guay; Daniel
Assignee(s): Merck Frosst Canada, Inc.
Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
Patent expiration dates:
- February 3, 2012
  ✓
  Patent use: PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
  ✓
  Drug substance
  ✓
  Drug product
- February 3, 2012
  ✓
  Patent use: PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
  ✓
  Drug substance
  ✓
  Drug product
- February 3, 2012
  ✓
  Patent use: ASTHMA
  ✓
  Drug substance
  ✓
  Drug product
- August 3, 2012
  ✓
  Patent use: ASTHMA
  ✓
  Pediatric exclusivity
- August 3, 2012
  ✓
  Pediatric exclusivity

Granule formation
Patent 8,007,830
Issued: August 30, 2011
Inventor(s): Down; Brian
Assignee(s): Merck Frosst Canada & Co.
The present invention relates to oral granules of montelukast sodium.
Patent expiration dates:
- October 24, 2022
  ✓
  Drug product

Has a generic version of Sinografin been approved?

No. There is currently no therapeutically equivalent version of Sinografin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sinografin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sinografin.

Has a generic version of Lamictal ODT been approved?

No. There is currently no therapeutically equivalent version of Lamictal ODT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lamictal ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Orally disintegrating tablet compositions of lamotrigine
Patent 7,919,115
Issued: April 5, 2011
Inventor(s): Venkatesh; Gopi M. & Vyas; Nehal H. & Gosselin; Michael & Lai; Jin-Wang
Assignee(s): Eurand, Inc.
The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
Patent expiration dates:
- January 4, 2029
  ✓
  Drug substance
  ✓
  Drug product

Has a generic version of Exelon been approved?

A generic version of Exelon has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Exelon and have been approved by the FDA:

rivastigmine tartrate capsule; oral

Manufacturer: DR REDDYS LABS INC

Approval date: October 31, 2007

Strength(s): EQ 1.5MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4.5MG BASE ^[AB], EQ 6MG BASE ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: October 22, 2007

Strength(s): EQ 1.5MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4.5MG BASE ^[AB], EQ 6MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: January 8, 2008

Strength(s): EQ 1.5MG BASE ^[AB], EQ 3MG BASE ^[AB], EQ 4.5MG BASE ^[AB], EQ 6MG BASE ^[AB]

Note: No generic formulation of the following products are available.

rivastigmine - film, extended release; transdermal

rivastigmine tartrate - solution; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Exelon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Phenyl carbamates
Patent 4,948,807
Issued: August 14, 1990
Inventor(s): Rosin; Marta W. & Chorev; Michael & Tashma; Zeev
Assignee(s): Proterra AG
Phenyl carbamates of the general formula ##STR1## wherein R.sub.1 to R.sub.5 are as defined in the claims, are useful as pharmaceuticals.
Patent expiration dates:
- August 14, 2012
  ✓
  Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA
  ✓
  Drug substance

Phenyl carbamate
Patent 5,602,176
Issued: February 11, 1997
Inventor(s): Enz; Albert
Assignee(s): Sandoz Ltd.
The (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenylncarbamate in free base or acid addition salt form is useful as pharmaceutical, particularly for systemic transdermal administration.
Patent expiration dates:
- February 11, 2014
  ✓
  Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA
  ✓
  Drug substance
  ✓
  Drug product
- February 11, 2014
  ✓
  Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA

TTS containing an antioxidant
Patent 6,316,023
Issued: November 13, 2001
Inventor(s): Asmussen; Bodo & Horstmann; Michael & Kopke; Kai & Tiemessen; Henricus L. G. M. & Dinh; Steven Minh & Gargiulo; Paul M.
Assignee(s): Novartis AG
LTS Lohmann Therapie-Systeme GmbH
Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an antioxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
Patent expiration dates:
- January 8, 2019
  ✓
  Drug product

TTS containing an antioxidant
Patent 6,335,031
Issued: January 1, 2002
Inventor(s): Bodo; Asmussen & Michael; Horstmann & Kai; Köpke & Henricus L. G. M.; Tiemessen & Steven Minh; Dinh & Paul M.; Gargiulo
Assignee(s): Novartis AG
LTS Lohmann Therapie-Systeme GmbH Co. KG
Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
Patent expiration dates:
- January 8, 2019
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- July 6, 2010 - NEW DOSAGE FORM

Has a generic version of Retisert been approved?

No. There is currently no therapeutically equivalent version of Retisert available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Retisert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Patent 6,217,895
Issued: April 17, 2001
Inventor(s): Guo; Hong & Ashton; Paul
Assignee(s): Control Delivery Systems
The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
Patent expiration dates:
- March 22, 2019
  ✓
  Patent use: TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
  ✓
  Drug product

Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Patent 6,548,078
Issued: April 15, 2003
Inventor(s): Hong; Guo & Paul; Ashton
Assignee(s): Control Delivery Systems
The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
Patent expiration dates:
- March 22, 2019
  ✓
  Patent use: TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- April 8, 2012 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Betoptic S been approved?

No. There is currently no therapeutically equivalent version of Betoptic S available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Betoptic S. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Betoptic S.

Related Exclusivities

Exclusivity expiration dates:
- December 8, 2010 - PEDIATRIC EXCLUSIVITY

Has a generic version of Byetta been approved?

No. There is currently no therapeutically equivalent version of Byetta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Byetta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Patent 5,424,286
Issued: June 13, 1995
Inventor(s): Eng; John
This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, fragments thereof, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.
Patent expiration dates:
- December 1, 2016
  ✓
  Patent use: STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
- December 1, 2016
  ✓
  Patent use: TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

Methods for regulating gastrointestinal motility
Patent 6,858,576
Issued: February 22, 2005
Inventor(s): Young; Andrew A. & Gedulin; Bronislava & Beeley; Nigel Robert Arnold & Prickett; Kathryn S.
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
Patent expiration dates:
- January 6, 2017
  ✓
  Patent use: REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

Methods for glucagon suppression
Patent 6,872,700
Issued: March 29, 2005
Inventor(s): Young; Andrew A. & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
Patent expiration dates:
- January 14, 2020
  ✓
  Patent use: LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4

Exendin agonist formulations and methods of administration thereof
Patent 6,902,744
Issued: June 7, 2005
Inventor(s): Kolterman; Orville G. & Young; Andrew A.
Assignee(s): Amylin Pharmaceuticals, Inc.
Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Patent expiration dates:
- January 14, 2020
  ✓
  Drug product

Use of exendins for the reduction of food intake
Patent 6,956,026
Issued: October 18, 2005
Inventor(s): Beeley; Nigel Robert Arnold & Bhavsar; Sunil
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Patent expiration dates:
- January 7, 2018
  ✓
  Patent use: REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

Pharmaceutical compositions containing exendins
Patent 7,297,761
Issued: November 20, 2007
Inventor(s): Beeley; Nigel Robert Arnold & Prickett; Kathryn S. & Bhavsar; Sunil & Young; Andrew & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Patent expiration dates:
- October 15, 2017
  ✓
  Drug product

Exendin pharmaceutical compositions
Patent 7,521,423
Issued: April 21, 2009
Inventor(s): Young; Andrew A. & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
Patent expiration dates:
- October 15, 2017
  ✓
  Drug product

Exendins and exendin agonists for weight reduction and obesity
Patent 7,741,269
Issued: June 22, 2010
Inventor(s): Young; Andrew A. & Bhavsar; Sunil & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Patent expiration dates:
- January 7, 2018
  ✓
  Patent use: USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

Has a generic version of Bystolic been approved?

No. There is currently no therapeutically equivalent version of Bystolic available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bystolic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions containing micronized nebivolol
Patent 5,759,580
Issued: June 2, 1998
Inventor(s): Jans; Eugeen Marie Jozef & Smans; Guido Franciscus & Gilis; Paul Marie Victor
Assignee(s): Janssen Pharmaceutica, N.V.
The present invention relates to pharmaceutical compositions containing as active ingredient micronized nebivolol of formula (I) and ways of preparing said compositions. ##STR1##
Patent expiration dates:
- June 2, 2015
  ✓
  Drug product

Method of lowering the blood pressure
Patent 6,545,040
Issued: April 8, 2003
Inventor(s): Raymond Mathieu; Xhonneux & Guy Rosalia Eugène; Van Lommen
Assignee(s): Janssen Pharmaceutica N.V.
A method of potentiating the effects of blood pressure reducing agents in warm-blooded animals, said method comprising administering to said warm-blooded animals of an effective amount of a blood pressure reducing agent and a 2,2′-iminobisethanol derivative.
Patent expiration dates:
- December 17, 2021
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- December 17, 2012 - NEW CHEMICAL ENTITY

Has a generic version of Brovana been approved?

No. There is currently no therapeutically equivalent version of Brovana available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brovana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
Patent 5,795,564
Issued: August 18, 1998
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor, Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased bronchial distribution when administered by inhalation.
Patent expiration dates:
- April 3, 2012
  ✓
  Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Formoterol process
Patent 6,040,344
Issued: March 21, 2000
Inventor(s): Gao; Yun & Hett; Robert & Fang; Kevin Q. & Wald; Stephen A. & Redmon; Martin P. & Senanayake; Chris Hugh
Assignee(s): Sepracor Inc.
A method is disclosed for the preparation of optically pure isomers of formoterol by the reaction of an optically pure 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy-.alpha.-methyl-N-(phenylmethyl)benzeneethanamine followed by debenzylation. Useful intermediates in the process are also disclosed, as are the novel L-tartrate salt of R,R-formoterol and pharmaceutical compositions thereof.
Patent expiration dates:
- November 12, 2016
  ✓
  Drug substance

Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Patent 6,068,833
Issued: May 30, 2000
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.
Patent expiration dates:
- April 3, 2012
  ✓
  Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Formoterol tartrate process and polymorph
Patent 6,472,563
Issued: October 29, 2002
Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Patent expiration dates:
- November 9, 2021
  ✓
  Drug substance

Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Patent 6,589,508
Issued: July 8, 2003
Inventor(s): Gunnar; Aberg & John; Morley
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.
Patent expiration dates:
- April 3, 2012
  ✓
  Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Formoterol tartrate polymorph
Patent 6,720,453
Issued: April 13, 2004
Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Patent expiration dates:
- November 9, 2021
  ✓
  Drug substance

Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
Patent 6,866,839
Issued: March 15, 2005
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
Patent expiration dates:
- April 3, 2012
  ✓
  Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Formoterol tartrate polymorph
Patent 7,145,036
Issued: December 5, 2006
Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Patent expiration dates:
- November 9, 2021
  ✓
  Drug substance

Formoterol tartrate process and polymorph
Patent 8,110,706
Issued: February 7, 2012
Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
Assignee(s): Sunovion Pharmaceuticals Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Patent expiration dates:
- November 9, 2021
  ✓
  Drug product

Has a generic version of Fragmin been approved?

No. There is currently no therapeutically equivalent version of Fragmin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fragmin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Fragmin.

Has a generic version of Fosamax been approved?

A generic version of Fosamax has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Fosamax and have been approved by the FDA:

alendronate sodium tablet; oral

Manufacturer: APOTEX

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: AUROBINDO PHARMA

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: AUSTARPHARMA LLC

Approval date: September 24, 2009

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: CADISTA PHARMS

Approval date: February 18, 2010

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: DR REDDYS LABS LTD

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: SUN PHARMA GLOBAL

Approval date: September 10, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: TEVA PHARMS

Approval date: February 6, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB], EQ 70MG BASE ^[AB]

Note: No generic formulation of the following product is available.

alendronate sodium - solution; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fosamax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Dry mix formulation for bisphosphonic acids with lactose
Patent 5,358,941
Issued: October 25, 1994
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
Patent expiration dates:
- December 2, 2012
- June 2, 2013
  ✓
  Pediatric exclusivity

Oral liquid alendronate formulations
Patent 5,462,932
Issued: October 31, 1995
Inventor(s): Brenner; Gerald S. & Katdare; Ashok V. & Pretzer; Denise & Whiteford; Donna T.
Assignee(s): Merck & Co., Inc.
Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.
Patent expiration dates:
- May 17, 2014
- November 17, 2014
  ✓
  Pediatric exclusivity

Dry mix formulation for bisphosphonic acids
Patent 5,681,590
Issued: October 28, 1997
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
Patent expiration dates:
- December 2, 2012
- June 2, 2013
  ✓
  Pediatric exclusivity

Method for inhibiting bone resorption
Patent 5,994,329
Issued: November 30, 1999
Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Patent expiration dates:
- July 17, 2018
  ✓
  Sponsor has requested patent be delisted
- January 17, 2019
  ✓
  Pediatric exclusivity

Method for inhibiting bone resorption
Patent 6,015,801
Issued: January 18, 2000
Inventor(s): Daifotis; Anastasia G. & Yates; A. John & Santora, II; Arthur C.
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for caring out the therapeutic methods disclosed herein.
Patent expiration dates:
- July 17, 2018
  ✓
  Sponsor has requested patent be delisted
- January 17, 2019
  ✓
  Pediatric exclusivity

Dry mix formulation for bisphosphonic acids
Patent 6,090,410
Issued: July 18, 2000
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
Patent expiration dates:
- December 2, 2012
- June 2, 2013
  ✓
  Pediatric exclusivity

Dry mix formulation for bisphosphonic acids
Patent 6,194,004
Issued: February 27, 2001
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
Patent expiration dates:
- December 2, 2012
- June 2, 2013
  ✓
  Pediatric exclusivity

Method for inhibiting bone resorption
Patent 6,225,294
Issued: May 1, 2001
Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Patent expiration dates:
- July 17, 2018
  ✓
  Sponsor has requested patent be delisted
- January 17, 2019
  ✓
  Pediatric exclusivity

Has a generic version of Renova been approved?

A generic version of Renova has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Renova and have been approved by the FDA:

tretinoin cream; topical

Manufacturer: SPEAR PHARMS

Approval date: September 15, 2005

Strength(s): 0.05% ^[AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Renova. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Oil-in-water emulsion containing tretinoin
Patent 6,531,141
Issued: March 11, 2003
Inventor(s): John; Marvel
Assignee(s): Ortho-McNeil Pharmaceutical, Inc.
The present invention relates to an oil-in-water emulsion containing tretinoin and the use thereof in mitigating skin disorders such as acne, photodamaged skin, wrinkles, mottled hyperpigmentation, tactile roughness, and yellowing of facial skin.
Patent expiration dates:
- March 7, 2020

Has a generic version of Cardizem LA been approved?

A generic version of Cardizem LA has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cardizem LA and have been approved by the FDA:

diltiazem hydrochloride tablet, extended release; oral

Manufacturer: WATSON LABS FLORIDA

Approval date: March 15, 2010

Strength(s): 120MG ^[AB], 180MG ^[AB], 240MG ^[AB], 300MG ^[AB], 360MG ^[AB], 420MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cardizem LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Extended release form of diltiazem
Patent 5,529,791
Issued: June 25, 1996
Inventor(s): Deboeck; Arthur M. & Baudier; Philippe R.
Assignee(s): Galephar P.R., Inc., Ltd.
An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.
Patent expiration dates:
- June 25, 2013

Cushioning wax beads for making solid shaped articles
Patent 6,923,984
Issued: August 2, 2005
Inventor(s): Remon; Jean Paul
Assignee(s): Universiteit Gent
Biologically inactive cushioning beads comprise at least one compressible cushioning component consisting essentially of a microcrystalline hydrocarbon wax or a natural wax, the said wax being at least 30% by weight of the biologically inactive cushioning beads. Such beads are useful for making solid shaped articles containing biologically active ingredients by compression.
Patent expiration dates:
- February 25, 2021
  ✓
  Drug product

Chronotherapeutic diltiazem formulations and the administration thereof
Patent 7,108,866
Issued: September 19, 2006
Inventor(s): Albert; Kenneth Stephen & Maes; Paul José
Assignee(s): Biovall Laboratories International SRL
A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
Patent expiration dates:
- December 17, 2019
  ✓
  Patent use: TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
  ✓
  Drug product

Has a generic version of Zanaflex been approved?

A generic version of Zanaflex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zanaflex and have been approved by the FDA:

tizanidine hydrochloride capsule; oral

Manufacturer: APOTEX INC

Approval date: February 3, 2012

Strength(s): EQ 2MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 6MG BASE ^[AB]

tizanidine hydrochloride tablet; oral

Manufacturer: ALPHAPHARM

Approval date: December 16, 2003

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: APOTEX

Approval date: January 16, 2004

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: CARACO

Approval date: September 29, 2003

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: COREPHARMA

Approval date: October 11, 2002

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: DR REDDYS LABS INC

Approval date: July 3, 2002

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: March 28, 2003

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: SANDOZ

Approval date: June 27, 2002

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: TEVA

Approval date: July 3, 2002

Strength(s): EQ 4MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zanaflex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method of reducing somnolence in patients treated with tizanidine
Patent 6,455,557
Issued: September 24, 2002
Inventor(s): Cara A.; Pellegrini & Paul; Stark
Assignee(s): Elan Pharmaceuticals, Inc.
An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.
Patent expiration dates:
- November 28, 2021

Thursday, October 27, 2016

LACRISERT (hydroxypropyl cellulose - insert; ophthalmic)

Has a generic version of Lacrisert been approved?

Related Patents

See also...

SPIRIVA (tiotropium bromide monohydrate - powder; inhalation)

Has a generic version of Spiriva been approved?

Related Patents

Related Exclusivities

See also...

SINGULAIR (montelukast sodium - granule; oral)

SINGULAIR (montelukast sodium - tablet, chewable; oral)

SINGULAIR (montelukast sodium - tablet; oral)

Has a generic version of Singulair been approved?

Related Patents

See also...

SINOGRAFIN (diatrizoate meglumine; iodipamide meglumine - solution; intrauterine)

Has a generic version of Sinografin been approved?

Related Patents

See also...

LAMICTAL ODT (lamotrigine - tablet, orally disintegrating; oral)

Has a generic version of Lamictal ODT been approved?

Related Patents

See also...

EXELON (rivastigmine - film, extended release; transdermal)

EXELON (rivastigmine tartrate - capsule; oral)

EXELON (rivastigmine tartrate - solution; oral)

Has a generic version of Exelon been approved?

rivastigmine tartrate capsule; oral

Related Patents

Related Exclusivities

See also...

RETISERT (fluocinolone acetonide - implant; intravitreal)

Has a generic version of Retisert been approved?

Related Patents

Related Exclusivities

See also...

BETOPTIC S (betaxolol hydrochloride - suspension/drops; ophthalmic)

Has a generic version of Betoptic S been approved?

Related Patents

Related Exclusivities

See also...

BYETTA (exenatide synthetic - injectable; subcutaneous)

Has a generic version of Byetta been approved?

Related Patents

See also...

BYSTOLIC (nebivolol hydrochloride - tablet; oral)

Has a generic version of Bystolic been approved?

Related Patents

Related Exclusivities

See also...

BROVANA (arformoterol tartrate - solution; inhalation)

Has a generic version of Brovana been approved?

Related Patents

See also...

FRAGMIN (dalteparin sodium - injectable; subcutaneous)

Has a generic version of Fragmin been approved?

Related Patents

See also...

FOSAMAX (alendronate sodium - solution; oral)

FOSAMAX (alendronate sodium - tablet; oral)

Has a generic version of Fosamax been approved?

alendronate sodium tablet; oral

Related Patents

See also...

RENOVA (tretinoin - cream; topical)

Has a generic version of Renova been approved?

tretinoin cream; topical

Related Patents

See also...

CARDIZEM LA (diltiazem hydrochloride - tablet, extended release; oral)

Has a generic version of Cardizem LA been approved?

diltiazem hydrochloride tablet, extended release; oral

Related Patents

See also...

ZANAFLEX (tizanidine hydrochloride - capsule; oral)

ZANAFLEX (tizanidine hydrochloride - tablet; oral)

Has a generic version of Zanaflex been approved?

tizanidine hydrochloride capsule; oral

tizanidine hydrochloride tablet; oral